Target Cell Models for CAR-T & CAR-NK Validation

Accelerate functional assays with a specialized ecosystem of native tumor lines, engineered antigens, and quantitative reporter systems.

Reliable functional assays are the cornerstone of successful immunotherapy development. CAR T and CAR NK efficacy depends on assays that accurately reflect tumor targeting and cytotoxic activity.

Tebubio provides a streamlined path to discovery by offering access to a specialized ecosystem of validated target models, ranging from native tumor lines to advanced reporter-based systems.

From Target Selection to Model Alignment

The path to a successful cell therapy starts with choosing the right cellular environment. We bridge the gap between your therapeutic target and the data required for translational and preclinical decision-making:

Target Selection: Whether targeting hematologic or solid tumors, the antigen choice dictates assay sensitivity.
Model Alignment: We match your target with the optimal cell system
- Native Tumor Lines: For maximum physiological relevance.
- Engineered Models: For controlled, reproducible antigen expression.
- Reporter Systems (e.g. luciferase): For quantitative readouts.

Target Model Mapping → Identify the Optimal Model for Your Specific Assay Needs

Our portfolio integrates Cytion’s deep catalog of native tumor lines, with BPS Bioscience’s validated reporter systems and ProMab’s specialized engineering, which provides both the engineered target models and the pre-validated effector cells.

The examples below represent the most common targets requested for CAR-T/NK functional assay development.

If your specific target or model is not listed, contact our technical team for expert guidance.

Target & Indications	Engineered Models ⤑ Controlled Expression	Native Models ⤑ Physiological Relevance	Reporter Systems ⤑ Quantitative Readouts	Effector Benchmark ⤑ Positive Control
CD19 B-ALL, NHL	PM-CD19-CHO CHO cell background enabling controlled CD19 surface expression and antigen-specific response evaluation.	300359 (Raji) Widely used native CD19⁺ B-cell lymphoma model for functional assay development.	78494 (Luc-NALM6) High-sensitivity bioluminescent monitoring of real-time cell lysis.	PM-CAR1002 Pre-validated CD19 CAR-T cells to benchmark assay sensitivity.
BCMA Multiple Myeloma	PM-BCMA-CHO Stable engineered system for primary screening of BCMA constructs.	300431 (RPMI-8226) Native human Multiple Myeloma line for physiological relevance.	79724 (BCMA-Luc CHO) Quantitative reporter line for precise potency (EC50) calculation.	PM-CAR1022 Benchmark BCMA CAR-T cells for potency assay validation.
HER2 Breast, Gastric	79612 (HER2-CHO) Engineered CHO clones with H/M/L density to test CAR sensitivity thresholds.	300333 (SK-BR-3) Native line with natural HER2 amplification for clinical context.	« Custom Reporter Integration Available »	PM-CAR1024 Validated HER2 CAR-T cells to serve as a functional positive control.
EGFR Glioblastoma, NSCLC	78145 (EGFRvIII-CHO) Mutation-specific engineered CHO clones enabling selective evaluation of EGFRvIII-targeted recognition.	300112 (A-431) Native epithelial carcinoma line with high wild-type EGFR expression, suitable for evaluating target selectivity versus EGFRvIII-specific constructs.	« Custom Reporter Integration Available »	PM-CAR1023 EGFR CAR-T cells for functional benchmarking and target-specific activation studies.
CD22 B-ALL, DLBCL	PM-CD22-CHO Stable recombinant expression enabling controlled evaluation of CD22-targeted activation.	305850 (Pfeiffer) Human B-cell lymphoma line reported to express CD22 alongside B-cell lineage markers.	79715 (CD22-Luc CHO) Luciferase-compatible engineered CD22 target cells for quantitative cytotoxicity assays.	PM-CAR1029 Pre-validated CD22 CAR-T cells for B-cell malignancy assay benchmarking.

Technical Deep-Dive: Real-time Bioluminescent Cytotoxicity Assays

Quantitative reporter systems streamline assay development and functional characterization workflows by providing a high-sensitivity, non-radioactive alternative to traditional methods.

Featured Solution: Firefly Luciferase NALM6 Cell Line

The Firefly Luciferase NALM6 Cell Line consists of human CD19⁺ NALM6 leukemia cells constitutively expressing firefly luciferase.

Real-time Quantitation: Luminescence is directly proportional to the number of viable CD19⁺ cells.
Linearity & Sensitivity: High signal-to-noise ratio ensures precise data even at low E:T ratios.
Direct Lysis Readout: CAR-T/NK-mediated killing results in an immediate, measurable loss of signal.
High-Throughput: Optimized for 96-well luminometry for rapid effector-to-target ratio screening.

Complete Your Immunotherapy Workflow

Beyond target cell models, Tebubio provides complementary solutions to support every stage of your CAR-T and CAR-NK development pipeline:

→ Custom Target Cell Line Engineering: Tailored target expression and reporter systems.
→ Effector Cells: Pre-validated, cryopreserved CAR T (CAR NK upon request) cells.
→ Functional Assays: Reporter-based cytotoxicity, immune activation, and potency assays.
→ Scientific & Technical Support: Guidance on target selection and assay optimization.

Tailored Solutions for Your CAR-T/NK Workflow

If your target antigen, tumor model, or reporter configuration is not listed, our technical team can help identify or develop a suitable solution for your project

Contact our Technical Support Team

By Tebubio